Oregon reports 4 more COVID-19 deaths, 197 cases; Johnson & Johnson vaccine due
State estimates 34,000 doses of single-dose vaccine due this week
PORTLAND, Ore. (KTVZ) There are four new COVID-19 related deaths in Oregon, raising the state’s death toll to 2,212, the Oregon Health Authority reported Monday, also confirming 34,000 doses of the new Johnson & Johnson vaccine are expected this week.
OHA reported 197 new confirmed and presumptive cases of COVID-19 as of 12:01 a.m. Monday, bringing the state total to 155,787.
Oregon to receive Johnson & Johnson vaccine
Johnson & Johnson’s single-dose vaccine has received an Emergency Use Authorization from the federal government, making it the third COVID-19 vaccine available for use in the United States.
PORTLAND, Ore. – Oregon is expected to receive 34,000 doses of the recently-approved Johnson & Johnson COVID-19 vaccine this week as the state nears a total of one million doses administered to Oregonians. The news was included in the Oregon Health Authority’s Monday report. Health authorities also reported 197 new coronavirus cases, bringing the state’s total to 155,787 since the pandemic began.
Coronavirus in Oregon: 197 cases, 4 deaths as state expects 34,000 doses from Johnson & Johnson
Updated Mar 02, 2021;
Facebook Share
The Oregon Health Authority announced 197 new cases of COVID-19 on Monday and four new deaths as state officials made plans for the new Johnson & Johnson single-dose coronavirus vaccine approved for use by the federal government.
Oregon will receive 34,000 doses of the vaccine this week, but the state anticipates less vaccines for the next two weeks after the initial allocation. A majority of the doses will go to local public health authorities and pharmacies, an agency spokesman said.
The U.S. Food and Drug Administration reported the vaccine was 66% effective for preventing moderate to severe COVID-19 starting 28 days after vaccination in clinical trials, which involved more than 43,000 participants in the United States, Latin America, Brazil and South Africa. It was 72% effective in the United States, the FDA reported.